cryoSPHERE probe launched in United States, designed exclusively for
post-operative pain block
MASON, Ohio--(BUSINESS WIRE)--Feb. 12, 2019--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management (LAAM),
today announced that it has launched the cryoICE® cryoSPHERE™
probe in the United States. The cryoSPHERE probe is the first device in
the cryoICE family solely dedicated to blocking pain by temporarily
ablating peripheral nerves.
The cryoSPHERE probe offers a unique 8mm ball-tip design, a bendable
distal shaft, and an ergonomic handle to provide cardiac, thoracic, and
general surgeons ease of use when applying the device to the targeted
peripheral nerves to block pain. The launch of the cryoSPHERE probe
demonstrates AtriCure’s commitment to continued innovation in Cryo Nerve
Block Therapy (cryoNB).
“The addition of the cryoSPHERE probe to our pain management portfolio
is a major breakthrough in cardiac and thoracic surgery,” said Mike
Carrel, President and Chief Executive Officer. “cryoSPHERE is the first
of its kind, designed specifically to freeze nerves in the chest wall.
With cryoSPHERE, surgeons can use cryoNB therapy to reduce their
patients’ post-operative pain.”
The cryoSPHERE technology uses a unique freezing method to temporarily
block nerves from transmitting pain signals. The block typically lasts
several months, during which time the nerve regenerates, giving the body
time to heal. Because of the long-lasting nature of the therapy,
physicians are adopting cryoNB as an adjunct to their pain management
modalities, offering a unique solution for patients undergoing
cardiothoracic surgery.
“Since incorporating the technique of a cryoNB in my thoracic surgical
practice several years ago, I have seen a remarkable improvement in
overall management of post-operative pain, post-operative recovery
times, and patient satisfaction,” said Dr. Curtis Quinn, Cardiothoracic
Surgeon, Elliott Health System, Manchester, NH. “The cryoSPHERE probe is
an impressive new tool dedicated to managing pain in patients undergoing
cardiothoracic surgery.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™
Ablation System is the first and only medical device to receive FDA
approval for the treatment of persistent Afib. AtriCure’s AtriClip Left
Atrial Appendage (LAA) Exclusion System products are the most widely
sold LAA management devices worldwide, with more than 170,000 implanted
to date. For more information, visit AtriCure.com or follow us on
Twitter @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190212005090/en/
Source: AtriCure, Inc.
Valerie Storch-Willhaus
Media Relations
Senior Director,
Corporate Marketing and Communications
(612) 605-3311
vstorch-willhaus@AtriCure.com
Andy Wade
Investor Relations
Senior Vice President and Chief
Financial Officer
(513) 755-4564
awade@AtriCure.com
